Results 201 to 210 of about 263,760 (324)

Prognostic Significance of Portal Vein Tumor Thrombus in Pancreatic Ductal Adenocarcinoma Treated With Chemoradiotherapy

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim To examine the significance of portal vein tumor thrombus (PVTT) as a prognostic factor for patients with pancreatic ductal adenocarcinoma (PDAC) treated with chemoradiotherapy (CRT) followed by surgery. Methods The study retrospectively examined 313 patients with borderline resectable (BR) or locally advanced (LA) PDAC who underwent CRT ...
Aoi Hayasaki   +9 more
wiley   +1 more source

Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. [PDF]

open access: yesHaematologica, 2013
Mian SA   +11 more
europepmc   +1 more source

The NF-κB inhibitor IκBα negates colon cancer cell migration, invasion, proliferation and tumor growth [PDF]

open access: yes, 2010
Al Marzouqi, Nadia   +9 more
core   +2 more sources

Management Strategies for Disappearing Colorectal Liver Metastases After Systemic Chemotherapy: Long‐Term Outcomes and Preoperative Prediction of ‘True Complete Response’

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Determining whether to resect disappearing liver metastases (DLMs) after chemotherapy for colorectal liver metastases (CRLMs) remains challenging. Methods Patients who underwent hepatectomy after systemic chemotherapy for initially unresectable CRLMs were reviewed. True complete response (CR) was defined as either resected DLMs with
Taihei Soma   +9 more
wiley   +1 more source

Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice

open access: yesMolecular and Cellular Biology, 1992
H. Kwan   +11 more
semanticscholar   +1 more source

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Pirtobrutinib (PBN), a non‐covalent BTK inhibitor, has been approved by the FDA for relapsed/refractory mantle cell lymphoma (MCL); however, resistance to PBN has been observed. To dissect the molecular dynamics driving PBN resistance, we performed integrative single‐cell multi‐omic profiling (scRNA‐seq, scATAC‐seq, and scDNA‐seq) on ...
Fangfang Yan   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy